Twist Bioscience Corporation

NASDAQ:TWST

Medical - Diagnostics & Research

Healthcare
$116.35 +2.59%

+$2.15 today

Market cap
$7.66B
Beta
2.21
P/E (TTM)
-64.5
EPS (TTM)
-$1.32
52W Low $23.30High $88.46

Volume 2.23M

Average 1.53M

TWST Pre-Tax Margin

Income before tax as a percentage of revenue.

Twist Bioscience CorporationNASDAQ: TWST

Pre-Tax Margin · Q4 FY2026 · quarter ended Sep 2026

Pre-tax margin widens to -17.1%

Pre-tax margin was -17.1% in Q4 FY2026, up 10.1 pp from a year earlier. On a trailing-twelve-month basis it was -28.4%, down 8.0 pp year over year. Over 3 fiscal years it widened by 54.6 pp.

Context

  • Pre-tax margin widened in 2 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
-17.1%+12.3 pp QoQ
Last fiscal yearSep 2026
-28.4%-8.0 pp YoY
LTMSep 2026
-28.4%-8.0 pp YoY
Pre-Tax Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+10.1 pp——
1 year-8.0 pp——
3 years+54.6 pp——
5 years——
10 years——

Pre-Tax Margin history

Percent of revenue · from the income statement

Latest · FY2026
-28.4%
Year-over-year change
-8.0pp

Pre-Tax Margin vs competitors

How TWST compares with its peers on the latest reported figures

  • TWST's LTM Sep 2026 pre-tax margin of -28.4% is the lowest of the 2 companies compared; the peer median is 6.6%.
  • Its year-over-year change of -8.0 pp is the lowest of 2, against a peer median of +8.7 pp.
  • Over three fiscal years its change of +54.6 pp compares with a peer median of -18.9 pp.
TWST Competitors Peer median
Pre-Tax Margin for TWST and competitors
Company Period LTM level YoY 3-year change
RGENRepligen CorporationLTM Jun 20266.6% +8.7 pp-18.9 pp
TWSTTwist Bioscience CorporationLTM Sep 2026-28.4% -8.0 pp+54.6 pp
Peer median (excluding TWST) 6.6%+8.7 pp-18.9 pp

Competitors are the stored peer set for TWST. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
FY2026
Sep 2026
Revenue203.57M245.11M312.97M376.57M459.43M
Cost of Revenue119.33M155.38M179.63M185.57M218.63M
Gross Profit84.24M89.73M133.35M191M240.8M
Gross Margin41.4%36.6%42.6%50.7%52.4%
Research & Development120.31M106.89M90.85M80.29M71.84M
Selling, General & Admin212.95M189.74M218.4M246.98M301.22M
Operating Expenses319.01M306.89M354.18M327.26M380.26M
Depreciation & Amortization16.51M29.31M31.43M24.85M0
EBITDA(211.68M)(174.15M)(176.71M)(52.1M)(129.8M)
EBITDA Margin-104.0%-71.1%-56.5%-13.8%-28.3%
Operating Income(234.78M)(217.16M)(220.83M)(136.26M)(139.46M)
Operating Margin-115.3%-88.6%-70.6%-36.2%-30.4%
Interest Income3.06M14.37M15.34M11.36M8.8M
Interest Expense80K5K29K00
Other Income / Expenses6.5M13.69M12.67M59.31M8.85M
Income Before Tax(228.27M)(203.47M)(208.17M)(76.95M)(130.61M)
Pre-Tax Margin-112.1%-83.0%-66.5%-20.4%-28.4%
Income Tax Expense(10.41M)1.15M560K719K(406K)
Net Income(217.86M)(204.62M)(208.73M)(77.67M)(130.2M)
Net Margin-107.0%-83.5%-66.7%-20.6%-28.3%
EPS (Basic)(4.04)(3.60)(3.60)(1.30)(2.08)
EPS (Diluted)(4.04)(3.60)(3.60)(1.30)(2.08)
Weighted Avg Shares53.89M56.89M58.02M59.81M62.62M
Weighted Avg Shares (Diluted)53.89M56.89M58.02M59.81M62.62M

Twist Bioscience Corporation

NASDAQ:TWST

Intrinsic Alpha fair value

Locked

Current Price

$116.35

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.